Paper41848748
Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.
Rowland T and 32 others. Clin Pharmacol Ther, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study. Papers, record 41848748. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41848748
- Disease
- COVID-19540 drugs
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.
- PubMed
- Publication types
- Journal Article, Clinical Trial, Phase I, Randomized Controlled Trial, Adaptive Clinical Trial, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
- PubMed
Connected records1
Records in the library's other databases whose lists name this one, each read from that database's own release: up to 20 of each kind, the most connected first.
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Amides | Major topic |
| Antiviral Agents | Major topic |
| COVID-19 Drug Treatment | Major topic |
| Pyrazines | Major topic |
| Aged | |
| Aged, 80 and over | |
| Female | |
| Humans | |
| Male | |
| Middle Aged | |
| Administration, Intravenous | |
| Bayes Theorem | |
| COVID-19 | |
| Dose-Response Relationship, Drug | |
| Hospitalization | |
| SARS-CoV-2 |
Source PubMed
Grants7
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 75F40120C00085 | US Food and Drug Administration | PubMed | ||
| NIHR300576 | National Institute for Health and Care Research | PubMed | ||
| National Institute for Health Research Southampton Biomedical Research Centre | PubMed | |||
| MR/V028391/1 | Medical Research Council | United Kingdom | PubMed | |
| MR/W005611/1 | Medical Research Council | United Kingdom | PubMed | |
| MC_UU_00040/03 | Medical Research Council | United Kingdom | PubMed | |
| 221590/Z/20/Z | Wellcome Trust | United Kingdom | PubMed |
Source PubMed
Trials1
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record |
|---|---|---|---|
| NCT04746183 | AGILE (Early Phase Platform Trial for COVID-19) | Derived from the trial | Yes |
Source ClinicalTrials.gov
References36
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28231247 | Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted. | PLoS Negl Trop Dis | 2017 | https://conductscience.org/library/papers/28231247 | PubMed |
| 2 | 30951731 | Cell line-dependent activation and antiviral activity of T-1105, the non-fluorinated analogue of T-705 (favipiravir). | Antiviral Res | 2019 | https://conductscience.org/library/papers/30951731 | PubMed |
| 3 | 32438446 | Prioritization of Anti-SARS-Cov-2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics. | Clin Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32438446 | PubMed |
| 4 | 27736754 | Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses. | Antimicrob Agents Chemother | 2017 | https://conductscience.org/library/papers/27736754 | PubMed |
| 5 | 32350860 | Dose Rationale for Favipiravir Use in Patients Infected With SARS-CoV-2. | Clin Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32350860 | PubMed |
| 6 | 39397762 | A seamless Phase I/II platform design with a time-to-event efficacy endpoint for potential COVID-19 therapies. | Stat Methods Med Res | 2024 | https://conductscience.org/library/papers/39397762 | PubMed |
| 7 | 34450619 | Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study. | J Antimicrob Chemother | 2021 | https://conductscience.org/library/papers/34450619 | PubMed |
| 8 | 33091434 | Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. | Antiviral Res | 2020 | https://conductscience.org/library/papers/33091434 | PubMed |
| 9 | 32679055 | In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2. | Antiviral Res | 2020 | https://conductscience.org/library/papers/32679055 | PubMed |
| 10 | 26930627 | Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. | PLoS Med | 2016 | https://conductscience.org/library/papers/26930627 | PubMed |
| 11 | 33741945 | Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model. | Nat Commun | 2021 | https://conductscience.org/library/papers/33741945 | PubMed |
| 12 | 35639525 | Favipiravir Treatment of Uncomplicated Influenza in Adults: Results of Two Phase 3, Randomized, Double-Blind, Placebo-Controlled Trials. | J Infect Dis | 2022 | https://conductscience.org/library/papers/35639525 | PubMed |
| 13 | 32943628 | Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis. | Nat Commun | 2020 | https://conductscience.org/library/papers/32943628 | PubMed |
| 14 | 31207186 | Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages. | CPT Pharmacometrics Syst Pharmacol | 2019 | https://conductscience.org/library/papers/31207186 | PubMed |
| 15 | 32251767 | Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. | Antiviral Res | 2020 | https://conductscience.org/library/papers/32251767 | PubMed |
| 16 | 32366720 | Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. | Antimicrob Agents Chemother | 2020 | https://conductscience.org/library/papers/32366720 | PubMed |
| 17 | 32020029 | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. | Cell Res | 2020 | https://conductscience.org/library/papers/32020029 | PubMed |
| 18 | 32246834 | Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection. | Clin Pharmacol Ther | 2020 | https://conductscience.org/library/papers/32246834 | PubMed |
| 19 | 37739792 | Oral Favipiravir Exposure and Pharmacodynamic Effects in Adult Outpatients With Acute Influenza. | J Infect Dis | 2024 | https://conductscience.org/library/papers/37739792 | PubMed |
| 20 | 32475019 | Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID-19. | Clin Transl Sci | 2020 | https://conductscience.org/library/papers/32475019 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42479031 | Pharmacokinetics of injectable favipiravir: phase I, randomized, double-blind, placebo-controlled study in healthy East Asian subjects. | Antimicrob Agents Chemother | 2026 | https://conductscience.org/library/papers/42479031 | PubMed |
| 42396859 | Favipiravir tissue distribution and inhibitory quotients in preclinical models: towards a pipeline for evidence-based antiviral repurposing. | J Antimicrob Chemother | 2026 | https://conductscience.org/library/papers/42396859 | PubMed |
| 42141199 | Favipiravir for Lassa fever: an open-label, randomized controlled phase 2 trial. | Nat Med | 2026 | https://conductscience.org/library/papers/42141199 | PubMed |
Drugs6
The drugs whose trials, in the Pipelines release, list the paper.
| Drug | ChEMBL ID | The trials list it as | Trials | In Drugs and targets | Source |
|---|---|---|---|---|---|
| NITAZOXANIDE | CHEMBL1401 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL1401 | ChEMBL |
| FAVIPIRAVIR | CHEMBL221722 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL221722 | ChEMBL |
| REMDESIVIR | CHEMBL4065616 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4065616 | ChEMBL |
| MOLNUPIRAVIR | CHEMBL4650320 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4650320 | ChEMBL |
| SOTROVIMAB | CHEMBL4650524 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4650524 | ChEMBL |
| BELUDAVIMAB | CHEMBL4802220 | Derived from the trial | 1 | https://conductscience.org/library/drugs/CHEMBL4802220 | ChEMBL |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Genes
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41848748
GET https://conductscience.org/api/papers/v1/41848748/authors?page=2